Head-to-head evidence
CT-996 vs XW003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
CT-996
Developed by Roche
NCT07081958 · Phase 2 · completed
The study randomized 352 participants to placebo or one of seven RO7795081 dosing regimens, with participants and investigators blinded. Its primary endpoint was the clinical measure of percent change in body weight at Week 30, but no results or statistical comparison have been posted, so the endpoint cannot yet be classified as met or missed.
Next expected readout: December 2026 · NCT06982131 (registry estimate)
XW003
Developed by Sciwind Biosciences
NCT05813795 · Phase 3 · completed
This randomized, triple-blind, placebo-controlled Phase 3 trial (n=664) in adults with overweight or obesity found that ecnoglutide (XW003) produced significantly greater weight loss than placebo at 40 weeks across all three doses tested, up to 13.2% versus about 0.1% with placebo (p<0.0001 for every dose).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07073417 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CT-996's landscape · XW003's landscape